Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trial.

ESMO Open · 2026 · PMC13325283 · PMID 42349245

Europe PMC DOI

hedged sentence

0.8100

closest p · 16.2× alpha

0.8100

boldest claim

The sentences

did not reach statistical significanceP = 0.81not close (p > 0.1)

Stable/decreasing CA19-9 was associated with a numerically longer median radiological PFS (4.3 months versus 3.3 months), but differences did not reach statistical significance (HR 1.08, 95% CI 0.55-2.14; P = 0.81).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.